Royalty Pharma Reports Q1 2026 Earnings and Provides Updated Guidance
Royalty Pharma (RPRX) reported strong financial performance for Q1 2026, with a Return on Invested Capital (ROIC) of 14.1% and Return on Invested Equity (ROIE) of 19.7%. The company deployed $528 million in investments and returned $186 million to shareholders through share repurchases and a 7% dividend increase. It also raised its 2026 full-year portfolio receipts guidance to between $3.325 billion and $3.45 billion.
Topics: capital deployment financial performance guidance update shareholder returns